Your browser is no longer supported. Please, upgrade your browser.
CLVS Clovis Oncology, Inc. daily Stock Chart
CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-7.19 Insider Own0.30% Shs Outstand71.66M Perf Week-8.10%
Market Cap653.52M Forward P/E- EPS next Y-2.50 Insider Trans-15.90% Shs Float86.16M Perf Month-15.51%
Income-413.30M PEG- EPS next Q-1.07 Inst Own41.30% Short Float24.85% Perf Quarter-8.10%
Sales152.50M P/S4.29 EPS this Y-5.20% Inst Trans-0.23% Short Ratio2.78 Perf Half Y-36.63%
Book/sh-1.77 P/B- EPS next Y35.20% ROA-61.80% Target Price- Perf Year-53.90%
Cash/sh2.42 P/C2.86 EPS next 5Y69.10% ROE394.80% 52W Range2.93 - 17.37 Perf YTD-33.62%
Dividend- P/FCF- EPS past 5Y-9.50% ROI-76.50% 52W High-60.16% Beta2.57
Dividend %- Quick Ratio2.20 Sales past 5Y60.00% Gross Margin76.10% 52W Low136.18% ATR0.82
Employees484 Current Ratio2.50 Sales Q/Q28.70% Oper. Margin- RSI (14)40.62 Volatility8.22% 11.03%
OptionableYes Debt/Eq- EPS Q/Q15.20% Profit Margin- Rel Volume0.96 Prev Close7.05
ShortableYes LT Debt/Eq- EarningsMay 05 AMC Payout- Avg Volume7.69M Price6.92
Recom2.90 SMA20-14.95% SMA50-5.81% SMA200-5.10% Volume7,416,535 Change-1.84%
May-18-20Reiterated H.C. Wainwright Buy $29 → $33
Apr-27-20Downgrade SVB Leerink Mkt Perform → Underperform $5
Apr-09-20Downgrade BofA/Merrill Neutral → Underperform $6
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
Aug-17-17Initiated Evercore ISI In-line $73
May-28-20 08:00AM  Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Business Wire
05:06AM  Edited Transcript of CLVS earnings conference call or presentation 5-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-21-20 04:10PM  Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program Business Wire
02:24PM  Clovis Oncology Needs a Savior GuruFocus.com
May-19-20 06:53PM  8 Biotechs Tapping Secondary Markets for $3 Billion GuruFocus.com -16.07%
03:09PM  Why Clovis Oncology's Stock Is Trading Lower Today Benzinga
May-18-20 08:05PM  Clovis Oncology Announces Pricing of Public Offering of Common Stock Business Wire -7.53%
04:02PM  Clovis Oncology Announces Proposed Offering of Common Stock Business Wire
11:45AM  Clovis' (CLVS) Rubraca Gets FDA Approval for Prostate Cancer Zacks
May-16-20 11:31AM  Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer Motley Fool
May-15-20 02:30PM  Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy Business Wire
May-14-20 10:18AM  Is Clovis Oncology (CLVS) Stock a Solid Choice Right Now? Zacks
May-11-20 11:00AM  Why Clovis Oncology Stock Marched Higher in April Motley Fool
May-06-20 11:17AM  Clovis (CLVS) Q1 Earnings and Revenues Surpass Estimates Zacks
11:02AM  Clovis Oncology (CLVS) Q1 2020 Earnings Call Transcript Motley Fool
08:02AM  Benzinga Pro's Top 5 Stocks To Watch for Wed., May 6, 2020: SNY, GRUB, CLVS, NTDOY, FDS Benzinga
May-05-20 07:05PM  Clovis Oncology (CLVS) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM  Clovis Oncology Announces First Quarter 2020 Operating Results Business Wire
May-03-20 09:25AM  Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates Benzinga
Apr-29-20 04:05PM  Clovis Oncology to Present at the Bank of America Health Care Conference 2020 Business Wire
Apr-28-20 12:34PM  Will Clovis Oncology (CLVS) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-22-20 09:00AM  Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock? Zacks
Apr-21-20 04:05PM  Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5 Business Wire
Apr-15-20 12:00PM  Clovis (CLVS) Upgraded to Buy: Here's Why Zacks
Apr-14-20 05:08PM  Clovis Oncology Announces Debt Exchange Transaction Business Wire
Apr-09-20 10:04AM  Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca Benzinga
Apr-03-20 05:50PM  Clovis Oncology (CLVS) Gains As Market Dips: What You Should Know Zacks
Mar-25-20 11:30AM  Why Is Clovis (CLVS) Down 41.6% Since Last Earnings Report? Zacks -5.14%
Mar-20-20 09:36AM  Is the Options Market Predicting a Spike in Clovis Oncology (CLVS) Stock? Zacks
Mar-19-20 05:50PM  Clovis Oncology (CLVS) Gains But Lags Market: What You Should Know Zacks
Mar-11-20 05:50PM  Clovis Oncology (CLVS) Stock Moves -1.59%: What You Should Know Zacks
Mar-03-20 08:30AM  Clovis Oncology to Present at the Barclays Global Healthcare Conference Business Wire
Mar-02-20 04:00AM  Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain Business Wire
Feb-27-20 07:24AM  Edited Transcript of CLVS earnings conference call or presentation 24-Feb-20 9:30pm GMT Thomson Reuters StreetEvents -8.49%
Feb-26-20 09:02AM  Here's What Analysts Are Forecasting For Clovis Oncology, Inc. After Its Full-Year Results Simply Wall St. -6.38%
Feb-25-20 10:12AM  Clovis (CLVS) Q4 Loss Wider Than Expected, Revenues Beat Zacks -19.46%
Feb-24-20 06:15PM  Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates Zacks -9.82%
04:05PM  Clovis Oncology Announces 2019 Operating Results Business Wire
Feb-21-20 11:30AM  Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year? Zacks
Feb-19-20 10:13AM  What's in Store for Aimmune (AIMT) This Earnings Season? Zacks +12.96%
09:39AM  Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4? Zacks
08:39AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Feb-17-20 12:30PM  Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
08:46AM  5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates Zacks
Feb-13-20 08:30AM  Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24 Business Wire
Feb-11-20 04:05PM  Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference Business Wire
Feb-06-20 03:34PM  4 Stocks Looking Higher During Earnings Season Benzinga
11:17AM  Four stocks to watch this week include Clovis Oncology and 3D Systems MarketWatch
Feb-03-20 09:44AM  Is a Beat in the Cards for Humana's (HUM) Earnings in Q4? Zacks
04:00AM  Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Business Wire
Jan-31-20 08:16AM  Have Insiders Been Buying Clovis Oncology, Inc. (NASDAQ:CLVS) Shares? Simply Wall St.
Jan-28-20 04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks
Jan-22-20 03:56PM  You can bring your skis to this Bay Area tech bank's new downtown Denver office American City Business Journals
09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks
Jan-16-20 09:09AM  Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review Zacks
Jan-15-20 04:11PM  Why This Highly Rated Biotech Stock Jumped As High As 26% Investor's Business Daily +5.96%
09:27AM  Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment MarketWatch
08:00AM  Clovis Oncologys Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer Business Wire
Jan-14-20 03:12PM  Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020 Zacks
Jan-07-20 07:26AM  Clovis Oncology Announces Debt Refinancing Transaction Business Wire -8.43%
07:25AM  Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019 Business Wire
Jan-02-20 08:55AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 12:08PM  FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug Zacks
Dec-18-19 10:31AM  Corporate News for Dec 18, 2019 Zacks
Dec-16-19 08:30AM  Initial Clinical Experience Reported from FAP-2286 Named-Patient Use at ICPO Symposium Business Wire -5.83%
Dec-10-19 08:35AM  Implied Volatility Surging for Clovis (CLVS) Stock Options Zacks +12.98%
Dec-09-19 07:18AM  Cramer Gives His Take On Bank Of America, BlackBerry And More Benzinga +11.45%
Dec-08-19 03:16PM  Did Hedge Funds Drop The Ball On Clovis Oncology Inc (CLVS) ? Insider Monkey
Dec-07-19 11:31AM  Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue? Zacks
Dec-06-19 01:41PM  ESG and Mission-Critical Issues for Director & Officer Liability CorpGov.com +8.47%
Dec-04-19 10:41AM  Immunomedics Resubmits Application for Breast Cancer Drug Zacks
Dec-02-19 05:41AM  Introducing Clovis Oncology (NASDAQ:CLVS), The Stock That Tanked 76% Simply Wall St. +10.05%
Nov-29-19 12:15PM  Biotech Tops in November: Best ETFs & Stocks Zacks +20.31%
11:01AM  Clovis Oncology, Inc. (CLVS) Shares March Higher, Can It Continue? Zacks
Nov-27-19 09:00AM  Clovis (CLVS) Looks Good: Stock Adds 6.3% in Session Zacks +13.64%
Nov-26-19 09:00AM  Clovis (CLVS) Upgraded to Buy: Here's Why Zacks +6.33%
Nov-22-19 12:56PM  3 Momentum Stocks To Watch Post-Earnings Benzinga +11.60%
12:50PM  Three momentum stocks to watch after company earnings reports MarketWatch
Nov-19-19 04:54PM  Teva, Bausch Could Be Next to File for Bankruptcy GuruFocus.com +10.34%
Nov-14-19 01:31PM  Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks Zacks
Nov-13-19 05:51AM  Edited Transcript of CLVS earnings conference call or presentation 7-Nov-19 1:30pm GMT Thomson Reuters StreetEvents +19.85%
04:00AM  Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy Business Wire
Nov-11-19 10:29AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks -8.50%
Nov-08-19 10:49AM  Were Hedge Funds Right About Dumping Clovis Oncology Inc (CLVS)? Insider Monkey +36.11%
09:32AM  Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up Zacks
Nov-07-19 09:25AM  Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates Zacks +20.50%
08:00AM  Clovis Oncology Announces Third Quarter 2019 Operating Results Business Wire
07:18AM  The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga
Oct-31-19 10:34AM  Analysts Estimate Clovis Oncology (CLVS) to Report a Decline in Earnings: What to Look Out for Zacks -6.76%
Oct-22-19 08:30AM  Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7 Business Wire
Oct-11-19 09:19AM  Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund Business Wire
Oct-09-19 11:22AM  Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook Zacks
Oct-08-19 11:08AM  Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks Benzinga -12.22%
Oct-04-19 10:31AM  J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug Zacks
Oct-02-19 07:47AM  Is Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Fair? Simply Wall St.
Sep-30-19 09:00AM  Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options Zacks
Sep-29-19 02:30AM  Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019 Business Wire
Sep-25-19 11:10AM  Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More Zacks
Sep-24-19 02:08PM  Clovis Oncology Call Volume Spikes After Downgrade Schaeffer's Investment Research -6.87%
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MUEHL DANIEL WSee RemarksMay 27Sale6.912471,70726,494May 28 07:41 PM
Gross Paul EdwardSee RemarksMay 05Sale8.102,21317,92520,895May 07 04:45 PM
IVERS-READ GILLIAN CSee RemarksMay 05Sale8.101,47511,948207,095May 07 04:16 PM
MUEHL DANIEL WSee RemarksMay 05Sale8.102,21317,92524,334May 07 04:15 PM
Rolfe LindseySee RemarksMay 05Sale8.101,67713,58444,430May 07 04:15 PM
Rolfe LindseySee RemarksApr 06Option Exercise3.0823,03470,94559,091Apr 08 04:00 PM
IVERS-READ GILLIAN CSee RemarksMar 20Sale4.608293,813204,821Mar 23 04:44 PM
Rolfe LindseySee RemarksMar 20Sale4.601,7287,94936,057Mar 23 04:42 PM
IVERS-READ GILLIAN CSee RemarksMar 03Sale7.206054,356203,404Mar 05 04:17 PM
MUEHL DANIEL WSee RemarksMar 03Sale7.204753,42022,480Mar 05 04:17 PM
Gross Paul EdwardSee RemarksMar 03Sale7.204753,42019,041Mar 05 04:15 PM
Rolfe LindseySee RemarksMar 03Sale7.206874,94634,020Mar 05 04:16 PM
MUEHL DANIEL WSee RemarksFeb 27Sale6.902791,92522,227Mar 02 04:17 PM
MUEHL DANIEL WSee RemarksFeb 04Sale8.4110,47288,07015,117Feb 06 04:19 PM
IVERS-READ GILLIAN CSee RemarksFeb 04Sale8.417,20460,586203,067Feb 06 04:16 PM
Rolfe LindseySee RemarksFeb 04Sale8.417,50363,10033,722Feb 06 04:15 PM
Gross Paul EdwardSee RemarksFeb 04Sale8.4110,47088,05311,944Feb 06 04:15 PM
Rolfe LindseySee RemarksDec 20Sale11.301,72919,53826,228Dec 26 04:16 PM
IVERS-READ GILLIAN CSee RemarksDec 20Sale11.308309,379195,274Dec 26 04:15 PM
MUEHL DANIEL WSee RemarksDec 03Sale14.594666,7999,626Dec 05 04:06 PM
Rolfe LindseySee RemarksDec 03Sale14.606749,84124,185Dec 05 04:06 PM
IVERS-READ GILLIAN CSee RemarksDec 03Sale14.595928,640193,852Dec 05 04:05 PM
Gross Paul EdwardSee RemarksDec 03Sale14.594666,7996,192Dec 05 04:05 PM
MUEHL DANIEL WSee RemarksNov 26Sale10.202422,4689,369Nov 29 04:05 PM
IVERS-READ GILLIAN CSee RemarksSep 20Sale4.808374,018193,509Sep 24 04:46 PM
Rolfe LindseySee RemarksSep 20Sale4.801,7448,37123,881Sep 24 04:45 PM
Rolfe LindseySee RemarksSep 04Sale5.217163,73021,875Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksSep 04Sale5.214952,5798,772Sep 06 04:45 PM
Gross Paul EdwardSee RemarksSep 04Sale5.214952,5795,642Sep 06 04:45 PM
IVERS-READ GILLIAN CSee RemarksSep 04Sale5.216303,282192,113Sep 06 04:45 PM
MUEHL DANIEL WSee RemarksAug 27Sale6.092391,4568,528Aug 28 04:15 PM
ATWOOD BRIAN GDirectorAug 20Option Exercise0.2925,8627,50025,862Aug 22 04:15 PM
BLAIR JAMES CDirectorAug 20Buy5.9720,000119,40020,000Aug 20 09:49 PM
BLAIR JAMES CDirectorAug 16Buy5.7020,000114,00033,439Aug 20 09:49 PM
MAHAFFY PATRICK JPresident and CEOAug 16Buy5.5950,000279,576968,787Aug 19 08:35 AM
SPICKSCHEN THORLEFDirectorAug 16Buy5.678,60048,76258,176Aug 16 05:45 PM
SPICKSCHEN THORLEFDirectorAug 14Buy5.469,20050,23249,576Aug 15 04:12 PM
KLINGENSTEIN PAUL HDirectorJul 29Option Exercise0.2925,8627,50059,327Jul 31 04:24 PM
Rolfe LindseySee RemarksJun 20Sale14.701,72825,40221,591Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 20Sale14.7082912,186191,788Jun 24 04:45 PM
IVERS-READ GILLIAN CSee RemarksJun 04Sale15.075778,695190,357Jun 06 04:48 PM
MUEHL DANIEL WSee RemarksJun 04Sale15.074536,8277,905Jun 06 04:46 PM
Gross Paul EdwardSee RemarksJun 04Sale15.074536,8274,001Jun 06 04:45 PM
Rolfe LindseySee RemarksJun 04Sale15.076559,87119,537Jun 06 04:45 PM